Brand Name
Naglazyme
Generic Name
Galsulfase
View Brand Information FDA approval date: June 09, 2005
Classification: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Form: Solution
What is Naglazyme (Galsulfase)?
NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI . NAGLAZYME has been shown to improve walking and stair-climbing capacity. NAGLAZYME is a hydrolytic lysosomal glycosaminoglycan -specific enzyme indicated for patients with Mucopolysaccharidosis VI . NAGLAZYME has been shown to improve walking and stair-climbing capacity .
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment